Survey: Are you obligated to get a COVID-19 vaccine?

Take 2 minutes to help us examine EMS influenza and COVID-19 vaccination policies, practices and perceptions


To better understand EMS agency vaccination mandates and provider practices, and how these might impact COVID-19 vaccination amongst frontline personnel, we surveyed EMS providers, supervisors and chiefs. More than 500 responses have provided insights into EMS vaccination policies, practices and perceptions. Read the results and weigh in: will you be vaccinated?

The CDC and the Advisory Committee on Immunization Practices recommends that all people aged 6 months and older be vaccinated against influenza, with emphasis given to those at high risk and healthcare providers. Many healthcare organizations require frontline personnel and those who work in hospitals and clinics be vaccinated for the flu.

While we look to Australia and countries experiencing their influenza season now to determine how COVID-19 will impact the U.S. 20/21 influenza season, manufacturers are furiously working to trial potential COVID-19 vaccines.

A recent article in JAMA, “Developing a SARS-CoV-2 Vaccine at Warp Speed,” authored by O’Callaghan KP, Blatz AM, and Offit PA, identified 5 leading COVID-19 candidates from Operation Warp Speed – a partnership between the U.S. Department of Health and Human Services and industry, with the goal of delivering 300 million doses of a safe and effective vaccine by January 2021.

To better understand EMS agency vaccination mandates, and provider practices, and how these might impact COVID-19 vaccination amongst frontline personnel, we’re surveying EMS providers about vaccination policies, practices and perceptions.  
To better understand EMS agency vaccination mandates, and provider practices, and how these might impact COVID-19 vaccination amongst frontline personnel, we’re surveying EMS providers about vaccination policies, practices and perceptions.   (Photo/Getty Images)

The candidates – including messenger RNA, recombinant vesicular stomatitis virus vector, replication-defective human adenovirus 26 and replication-defective simian adenovirus vector technology – are in various phases of production, from preclinical to Phase 2a clinical trials.

The U.S. has agreed to pay nearly $2 billion for 100 million doses of a potential COVID-19 vaccine being developed by U.S. drugmaker Pfizer and its German partner BioNTech.

To better understand EMS agency vaccination mandates, and provider practices, and how these might impact COVID-19 vaccination amongst frontline personnel, we’re surveying EMS providers about vaccination policies, practices and perceptions.  

Please take a few moments to complete the survey below and pass it along to your colleagues. We’ll share the results in a future article. Thank you for your participation.

Read next: Face masks: Here’s what cops, firefighters, medics and COs have to say about use, policy and effectiveness

Recommended for you

Join the discussion

The EMS news & trends you need, delivered right to your inbox.

Thanks! You've been successfully signed up for the EMS1 Daily

Copyright © 2021 EMS1. All rights reserved.